Valink presents at Curious2024 Ignite Session

At Curious2024 Future Insight on July 10-11 in Mainz, Germany, Arne Scheu represented Valink Therapeutics with an Ignite talk https://www.curiousfutureinsight.org/agenda/

The talk was selected from 250+ abstracts. Further information, including materials, are available on request at connect@valinktx.com

‍

Abstract. Antibody-drug conjugates (ADCs) are now an established modality in oncology. ADCs utilise the specific antigen binding of antibodies to deliver cytotoxic payloads to tumour cells. Recently, bispecific ADCs (bsADCs) have arisen as a promising approach to improve selectivity of ADCs, enhancing efficacy and safety. Despite broad potential, the discovery of bsADCs is restricted by the lack of technologies for rapid generation and screening of therapeutic candidates. We have developed a multi-part assembly approach for the generation of bsADCs with a 1-week turnaround time from design to HTS experiments (1,000+/week). The low burden of bsADC generation enables discovery to start from functional assays, such as cytotoxicity, without requiring pre-assessment of unconjugated bispecific antibodies (e.g. internalisation). Our platform can rapidly switch formats, binders, linkers, and payloads, enabling unbiased screening of bsADCs for rapid hypothesis generation and drug lead identification.